Abstract
Objectives We aimed to evaluate the categorisation and clinical relevance of DRPs identified by community pharmacists, and further, to assess the quality of interventions with the patients and the physicians as documented by the pharmacists. Setting 23 Norwegian community pharmacies. Method Patients with type 2 diabetes were recruited by 24 community pharmacists who performed structured medication reviews based on the patients’ drug profiles and patient interviews. The DRPs identified were subsequently categorised. An evaluation group (EG) retrospectively evaluated the reviews. Clinical/practical relevance of each DRP and quality of community pharmacists’ intervention with patients and physician were scored. Average agreement between the EG and the community pharmacists was calculated. Internal agreement in the EG was calculated using a modified version of Fleiss’ Kappa coefficient. Results A total of 73 patients were included (mean age 62 years, 52% female, on average prescribed 8.7 drugs). The pharmacists identified 88 DRPs in 43 of the patients. The most common DRPs were adverse drug reactions (22%) and wrong drug or dose used by patient (14%). Anti-diabetic drugs and lipid modifying drugs were associated with the most DRPs. The EG agreed with detection and categorisation of DRPs in more than 80% of the cases. The clinical/practical relevance of the detected DRPs was scored by the EG to be high or medium in 87% of the cases. The quality of the follow-up with patients and physicians was scored to be good or satisfactory in 93 and 98% of the cases, respectively. Conclusions Pre-defined categories of DRPs supported by structured forms were reliable and valid tools for identifying DRPs. The evaluation demonstrated that community pharmacists were able to identify DRPs of high to medium clinical/practical relevance, and to perform follow-ups of the DRPs with the patients and the physicians with a good or satisfactory quality.
Similar content being viewed by others
References
Doucette WR, McDonough RP, Klepser D, McCarthy R. Comprehensive medication therapy management: identifying and resolving drug-related issues in a community pharmacy. Clin Ther. 2005;27(7):1104–11.
Gray S, Woolfrey S, Copeland R, Gill D, Dennett G. Evaluating the potential impact of community pharmacy interventions on patient care in Northumberland. Qual Prim Care. 2004;12(1):47–51.
Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y. Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. J Clin Pharm Ther. 2006;31(5):409–19.
Granas AG, Bates I. The effect of pharmaceutical review of repeat prescribing in general practice. Int J Pharm Pract. 1999;7(7):264–75.
Viktil KK, Blix HS, Moger TA, Reikvam A. Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRPs). Pharmacoepidemiol Drug Saf. 2006;15(9):667–74.
van Mil JW, Westerlund LO, Hersberger KE, Schaefer MA. Drug-related problem classification systems. Ann Pharmacother. 2004;38(5):859–67.
Ernst ME, Doucette WR, Dedhiya SD, Osterhaus MC, Kumbera PA, Osterhaus JT, et al. Use of point-of-service health status assessments by community pharmacists to identify and resolve drug-related problems in patients with musculoskeletal disorders. Pharmacother. 2001;21(8):988–97.
Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) study. Qual Saf Health Care. 2003;12(3):176–80.
Blix HS, Viktil KK, Reikvam A, Moger TA, Hjemaas BJ, Pretsch P, et al. The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals. Eur J Clin Pharmacol. 2004;60(9):651–8.
Hanlon JT, Lindblad CI, Gray SL. Can clinical pharmacy services have a positive impact on drug-related problems and health outcomes in community-based older adults? Am J Geriatr Pharmacother. 2004;2(1):3–13.
Krass I, Taylor SJ, Smith C, Armour CL. Impact on medication use and adherence of Australian pharmacists’ diabetes care services. J Am Pharm Assoc. 2005;45(1):33–40.
Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195–200.
Wermeille J, Bennie M, Brown I, McKnight J. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team–a pilot study. Pharm World Sci. 2004;26(1):18–25.
Haugbolle LS, Sorensen EW. Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma—interviewing patients at home. Pharm World Sci. 2006;28(4):239–47.
Watson MC, Norris P, Granas AG. A systematic review of the use of simulated patients and pharmacy practice research. Int J Pharm Pract. 2006;14(2):83–93.
WHO Collaborating Centre for Drug Statistics Methodology. 2005. WHO Collaborating Centre, Oslo, Norway. http://www.whocc.no.
Ruths S, Viktil KK, Blix HS. Classification of drug-related problems. Tidsskr Nor Laegeforen. 2007;127(23):3073–6.
A language and environment for statistical computing. R-project org. 2007. [cited 2008 Mar. 13]. http://www.R-project.org.
Fleiss JL, Cuzick J. The reliability of dichotomous judgement: unequal number of judgements per subject. Appl Psychol Meas. 1979;3:537–42.
Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 2007.
Nathan A, Goodyer L, Lovejoy A, Rashid A. ‘Brown bag’ medication reviews as a means of optimizing patients’ use of medication and of identifying potential clinical problems. Fam Pract. 1999;16(3):278–82.
Britten N, Stevenson FA, Barry CA, Barber N, Bradley CP. Misunderstandings in prescribing decisions in general practice: qualitative study. BMJ. 2000;320(7233):484–8.
Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Ann Pharmacother. 2007;41(10):1569–82.
Lee SS, Schwemm AK, Reist J, Cantrell M, Andreski M, Doucette WR, et al. Pharmacists’ and pharmacy students’ ability to identify drug-related problems using TIMER (Tool to Improve Medications in the Elderly via Review). Am J Pharm Educ. 2009;73(3):52.
Kjome RL, Sandberg S, Granas AG. Diabetes care in Norwegian pharmacies: a descriptive study. Pharm World Sci. 2008;30(2):191–8.
Gorard DA. Escalating polypharmacy. QJM. 2006;99(11):797–800.
Haavik S, Horn AM, Mellbye KS, Kjonniksen I, Granas AG. Prescription errors—dimension and measures. Tidsskr Nor Laegeforen. 2006;126(3):296–8.
Mandt I, Horn AM, Ekedahl A, Granas AG. Community pharmacists’ prescription intervention practices—exploring variations in practice in Norwegian pharmacies. Res Soc Adm Pharm. 2010;6(1);6–17.
Mandt I, Horn AM, Granas AG. Communication about prescription interventions between pharmacists and general practitioners. Tidsskr Nor Laegeforen. 2009;129(18):1846–9.
MacRae F, Lowrie R, Kinn S, Fish A. Patient views of pharmacist-led medication review clinics: a preliminary study. Int J Pharm Prac. 2003;11:R6.
Bero LA, Lipton HL, Bird JA. Characterization of geriatric drug-related hospital readmissions. Med Care. 1991;29(10):989–1003.
Allenet B, Bedouch P, Rose FX, Escofier L, Roubille R, Charpiat B, et al. Validation of an instrument for the documentation of clinical pharmacists’ interventions. Pharm World Sci. 2006;28(4):181–8.
van Roozendaal BW, Krass I. Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes. Pharm World Sci. 2009;31(5):580–95.
Acknowledgments
The Department of Postgraduate and Continuing Education, School of Pharmacy, University of Oslo, for organisational support.
Funding
The Norwegian Directorate of Health partially funded of the study.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Anne Marie Horn—Deceased.
Rights and permissions
About this article
Cite this article
Granas, A.G., Berg, C., Hjellvik, V. et al. Evaluating categorisation and clinical relevance of drug-related problems in medication reviews. Pharm World Sci 32, 394–403 (2010). https://doi.org/10.1007/s11096-010-9385-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-010-9385-x